Is Viking Therapeutics Stock a Buy?

The company is in the spotlight for one of its programs, but it's got others that also have promise. One of the current stars of the biotech world is Viking Therapeutics (VKTX -1.11%), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if approved, would compete in the white-hot market for weight loss medications. While that's not the only product in the company's pipeline, it's the one that many investors have pinned their hopes on. Typically, for a ...